KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $2.2 billion.

  • Halozyme Therapeutics' Liabilities and Shareholders Equity rose 487.25% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 billion, marking a year-over-year increase of 1139.16%. This contributed to the annual value of $2.1 billion for FY2024, which is 1905.11% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Liabilities and Shareholders Equity of $2.2 billion as of Q3 2025, which was up 487.25% from $2.1 billion recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Liabilities and Shareholders Equity registered a high of $2.2 billion during Q3 2025, and its lowest value of $966.6 million during Q1 2021.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $1.8 billion (2022), whereas its average is $1.7 billion.
  • In the last 5 years, Halozyme Therapeutics' Liabilities and Shareholders Equity soared by 12621.27% in 2021 and then tumbled by 587.78% in 2023.
  • Halozyme Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $1.1 billion in 2021, then skyrocketed by 66.74% to $1.8 billion in 2022, then decreased by 5.88% to $1.7 billion in 2023, then grew by 19.05% to $2.1 billion in 2024, then rose by 7.65% to $2.2 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $2.2 billion for Q3 2025, versus $2.1 billion for Q2 2025 and $2.2 billion for Q1 2025.